-
公开(公告)号：EP1220950A2
公开(公告)日：2002-07-10
申请号：EP00962602.9
申请日：2000-09-12
CPC分类号： C12Q1/6809 , C12N15/1034 , C12Q1/6837
摘要： The invention concerns novel methods for determining the toxic potential of test compounds, as well as equipment and kits for implementing said methods. The invention also concerns methods for generating nucleic acid sequences for use as genetic markers of toxicity. The invention is based in particular on the constitution of differential libraries of nucleic acids, characteristic of situations wherein the viability and/or cell proliferation are disrupted, and for demonstrating that said libraries are useful for very dependably assessing with high degree of sensitivity the toxic profile of compounds. The invention is particularly useful in the pharmaceutical industry, for analysing the toxic profile of molecules to be used for pharmaceutical preparation and/or in pharmaceutical compositions.
-
2.发明授权
公开(公告)号：EP1594498B1
公开(公告)日：2009-07-22
申请号：EP04712083.7
申请日：2004-02-18
IPC分类号： A61K31/437 , A61K31/444 , A61K31/706 , A61P27/06 , A61P27/02
CPC分类号： A61K31/437 , A61K31/444 , A61K31/706
摘要： The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods for the detection, characterisation and/or treatment (or management) of neurodegenerative pathologies. The invention also relates to methods for the identification or screening of compounds active in the aforementioned pathologies. The invention further relates to the compounds, genes, cells, plasmids or compositions which are used to carry out the above-mentioned methods. The invention is based on the identification of the role of phosphodiesterase 4B, the peripheral benzodiazepine receptor (PBR) and GABA(A)-type GABA receptors in neurodegenerative pathologies. In addition, the invention outlines the use of same as therapeutic, diagnostic or experimental markers or targets for said disorders.
-
公开(公告)号：EP1062364B1
公开(公告)日：2005-05-11
申请号：EP99909002.0
申请日：1999-03-11
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6809 , C12Q1/6827 , C12Q1/6837 , C12Q2539/105 , C12Q2537/113 , C12Q2521/301 , C12Q2565/501
摘要： The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridisation of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridisation of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.
-
公开(公告)号：EP1062364A1
公开(公告)日：2000-12-27
申请号：EP99909002.0
申请日：1999-03-11
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6809 , C12Q1/6827 , C12Q1/6837 , C12Q2539/105 , C12Q2537/113 , C12Q2521/301 , C12Q2565/501
摘要： The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridisation of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridisation of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.
-
5.发明公开UTILISATION DE PYRAZOLOPYRIDINES POUR LE TRAITEMENT DE DEFICITS COGNITIFS 有权PYRAZOLOPYRIDINEN的认知赤字的治疗
公开(公告)号：EP1638559A1
公开(公告)日：2006-03-29
申请号：EP04767477.5
申请日：2004-06-25
IPC分类号： A61K31/437 , A61P25/16 , A61P25/28
CPC分类号： A61K31/437
摘要： The invention relates to methods which are used to improve, increase or facilitate the cognition of individuals with neurodegenerative pathologies. More specifically, the invention relates to the use of compounds from the family of pyrazolopyridines in order to improve the cognitive faculties of individuals with neurodegenerative diseases. The invention can be used to improve the condition of individuals with different neurodegenerative diseases and, in particular, Alzheimer's disease and vascular dementia.
-
6.发明授权MARQUEURS GENETIQUES DE LA TOXICITE, PREPARATION ET UTILISATION 有权MAR GEN GEN DE DE TO，，，PR PR PR PR PR PR PR PR U
公开(公告)号：EP1220950B9
公开(公告)日：2004-11-03
申请号：EP00962602.9
申请日：2000-09-12
CPC分类号： C12Q1/6809 , C12N15/1034 , C12Q1/6837
摘要： The invention concerns novel methods for determining the toxic potential of test compounds, as well as equipment and kits for implementing said methods. The invention also concerns methods for generating nucleic acid sequences for use as genetic markers of toxicity. The invention is based in particular on the constitution of differential libraries of nucleic acids, characteristic of situations wherein the viability and/or cell proliferation are disrupted, and for demonstrating that said libraries are useful for very dependably assessing with high degree of sensitivity the toxic profile of compounds. The invention is particularly useful in the pharmaceutical industry, for analysing the toxic profile of molecules to be used for pharmaceutical preparation and/or in pharmaceutical compositions.
摘要翻译： 本发明涉及用于确定测试化合物的潜在毒性的新方法，以及用于实施所述方法的设备和试剂盒。 本发明还涉及产生用作毒性遗传标记的核酸序列的方法。 本发明特别基于核酸不同文库的构成，其特征在于其生存力和/或细胞增殖被破坏，并且用于证明所述文库可用于非常可靠地以高度灵敏度评估毒性谱 的化合物。 本发明在制药工业中特别有用，用于分析待用于药物制剂和/或药物组合物的分子的毒性特征。
-
公开(公告)号：EP1417349A2
公开(公告)日：2004-05-12
申请号：EP02777405.8
申请日：2002-08-13
CPC分类号： C12Q1/44 , A61K31/00 , C12Q1/6883 , C12Q2600/158
摘要： The invention relates to the field of biology, genetics and medicine and to novel methods of detecting, characterising and/or treating (or managing) neurodegenerative pathologies, particularly amyotrophic lateral sclerosis. Said invention also relates to methods of identifying or screening active compounds in said pathologies. Moreover, the invention relates to compounds, genes, cells, plasmids or compositions that can be used to carry out the above-mentioned methods. In particular, the invention outlines the role of PDE4B in said pathologies and the use thereof as a therapeutic, diagnostic or experimental target.
-
公开(公告)号：EP1198595A1
公开(公告)日：2002-04-24
申请号：EP00962576.5
申请日：2000-09-05
IPC分类号： C12Q1/68
CPC分类号： G01N33/56972 , C12Q1/6809
摘要： The invention concerns novel compositions and methods for detecting pathological events. More particularly, it concerns methods for detecting in vitro the presence of a pathology or a pathological event in a subject, which consists in taking a sample of the subject's blood cells and in determining the presence, in said sample, blood cells having a physiological condition characteristic of the pathology. The invention also concerns instruments, kits and compositions for implementing said methods, and their used in the field of human and animal health care, or in experimental research for example.
-
公开(公告)号：EP1417349B1
公开(公告)日：2008-11-19
申请号：EP02777405.8
申请日：2002-08-13
CPC分类号： C12Q1/44 , A61K31/00 , C12Q1/6883 , C12Q2600/158
摘要： The invention relates to the field of biology, genetics and medicine and to novel methods of detecting, characterising and/or treating (or managing) neurodegenerative pathologies, particularly amyotrophic lateral sclerosis. Said invention also relates to methods of identifying or screening active compounds in said pathologies. Moreover, the invention relates to compounds, genes, cells, plasmids or compositions that can be used to carry out the above-mentioned methods. In particular, the invention outlines the role of PDE4B in said pathologies and the use thereof as a therapeutic, diagnostic or experimental target.
-
10.发明公开COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS 有权化合物和方法治疗增生性疾病和关节炎性视网膜病变
公开(公告)号：EP1597253A2
公开(公告)日：2005-11-23
申请号：EP04715422.4
申请日：2004-02-27
发明人： LEBLOND, Bertrand , PETIT, Silvère , PICARD, Virginie , TAVERNE, Thierry , SCHWEIGHOFFER, Fabien
IPC分类号： C07D405/12 , C07D411/12 , A61K31/351 , A61K31/4709 , A61P35/00
CPC分类号： C07D405/12 , C07D411/12
摘要： The present invention relates to compounds having a general formula (I) and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having anti-proliferative and antiangiogenic activities, as well as methods for treating various diseases associated with abnormal cell proliferation, including cancer, or associated with unregulated angiogenesis including growth and metastasis of solid tumors, ocular diseases and especially retinopathies, or arthritis, by administering said compounds. It further deals with pharmaceutical compositions comprising said compounds, more particularly useful to treat cancers (such as leukemia), ocular diseases and arthritis.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.022 秒)
